[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address Please contact the publisher to request reinstatement.
[Skip to Content Landing]
June 24, 1992

Intravenous Immunoglobulin Therapy for Toxic Shock Syndrome

Author Affiliations

From the University of Connecticut Health Center, Farmington (Drs Barry, Hudgins, Donta, and Pesanti) and the Department of Veterans Affairs Medical Center, Newington, Conn (Drs Donta and Pesanti). Dr Hudgins is now with the University of Arizona College of Medicine, Phoenix.

JAMA. 1992;267(24):3315-3316. doi:10.1001/jama.1992.03480240077038

Staphylococcus aureus and group A Streptococcus pyogenes produce toxic shock syndrome characterized by hypotension and multisystem organ failure. While conventional therapy has consisted of antibiotics and intensive supportive care, some experimental evidence suggests that immunoglobulins directed against the toxins may be effective additional therapy. We report a case of "toxic strep syndrome" in which intravenous immunoglobulin was administered when signs and symptoms were worsening while the patient was receiving conventional therapy. Within hours of administration of the intravenous immunoglobulin, the patient experienced dramatic clinical improvement. This response suggests a possible therapeutic benefit of intravenous immunoglobulin in toxic shock syndrome.

(JAMA. 1992;267:3315-3316)